With conflict in the Middle East bringing on a global energy market squeeze, one major pharma supplier is raising prices ...
Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...
Iterum took its time launching Orlynvah, debuting the drug in August 2025, almost a full year after securing approval. That ...
Despite a healthy roster of late-stage assets and a revenue turnaround in 2025, it’s no secret that Biogen has been seeking ...
Insulet has reinstated the chief commercial officer position nearly three years after eliminating the role to pursue more ...
Amid a major corporate overhaul, Novo Nordisk is pruning the ranks at its production facility in Bloomington, Indiana, which ...
With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...
Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a ...
After high-profile moves by Eli Lilly and other Big Pharmas to pause their U.K. | The company is looking to work out an ...
After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq (daridorexant) is one step closer to potentially becoming a first-in-class treatment for children. | After notching a phase 2 trial ...
With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit. | Rocket ...
Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results